Data from EMC - Curated by Toby Galbraith - Last updated 06 July 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

RIXUBIS is indicated in patients of all age groups.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure


Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients

Visit Oral Anticoagulation Reversal


Related Content

More information

Category Value
Agency product number EMEA/H/C/003771
Orphan designation No
Date First Approved 19-12-2014
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Baxalta Innovations GmbH